Allogeneic(or not?), mesenchymal stem cell trial, double blind, Phase I, for myocardial infarction without immunosuppresion. It's a two year study. Congestive heart failure is the primary endpoint, IMHO.
8 posted on 04/23/2006 11:33:36 AM PDT by neverdem
(May you be in heaven a half hour before the devil knows that you're dead.)